Art. -Nr.: HY-164853

Kanglexin

Kundenbewertung

Based on 1 Customer Validation

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.65%
CAS. Nr.: 2228847-12-7
Formel: C₂₁H₁₈O₈
Molecular Weight:398.36

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Kanglexin Chemical Structure

CAS. Nr.: 2228847-12-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

NLRP3

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle AMPK Isoform-spezifische Produkte anzeigen :

In Vitro

Kanglexin (10-20 μM; 24 h) inhibits pyroptosis of cardiomyocytes treated with hypoxia or LPS (HY-D1056)^[1].
Kanglexin (5-20 μM; 24 h) reduces lipid levels in Oleic acid (HY-N1446) treated HepG2 cells through AMPK/SREGBP-2/PCSK9/LDLR signaling pathway^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

LPS (HY-D1056) treated neonatal mouse ventricular cardiomyocytes
Concentration:

10 μM
Incubation Time:

24 h
Result:

Inhibited the levels of NLRP3 and the pyroptosis-related proteins mature IL-1β and IL-18.

In Vivo

Kanglexin (20-40 mg/kg; oral gavage; 7 days) has an ameliorative effect in the myocardial infarction mouse model^[1].
Kanglexin (20-80 mg/kg; oral administration; 2 weeks) has an ameliorative effect in the hyperlipidemia rat model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice aged 8 weeks old (20 ± 2 g) with myocardial infarction (MI) model^[1]
Dosage:

20 and 40 mg/kg
Administration:

Oral gavage (i.g.); 7 days
Result:

Reduced myocardial injury in MI mice.
Effectively inhibited pyroptosis processes in the mouse hearts with MI.
Attenuated the activation of the NLRP3 inflammasome upon MI in mouse hearts.

Animal Model:

High fat diet treated Sprague-Dawley rats^[2]
Dosage:

20, 40 and 80 mg/kg
Administration:

Oral administration (p.o.); 2 weeks
Result:

Had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight.

Chemical Information

CAS. Nr. 2228847-12-7
Appearance Solid
Molecular Weight 398.36
Formel C₂₁H₁₈O₈
Color Light yellow to yellow
SMILES

O=C1C2=C(C(C3=C(C=C(C)C=C13)O)=O)C(O)=CC(OC(CCC(OCC)=O)=O)=C2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (62.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5103 mL

12.5515 mL

25.1029 mL

5 mM

0.5021 mL

2.5103 mL

5.0206 mL

10 mM

0.2510 mL

1.2551 mL

2.5103 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Bian Y, et al. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacol Sin. 2020 Mar;41(3):319-326. [Content Brief]

[2]. Li X, et al. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway. Biomed Pharmacother. 2021 Jan;133:110802. [Content Brief]

[3]. Yang S, et al. Kanglexin counters vascular smooth muscle cell dedifferentiation and associated arteriosclerosis through inhibiting PDGFR. Phytomedicine. 2024 Jul 25;130:155704. [Content Brief]

[4]. Zhao Y, et al. Kanglexin accelerates diabetic wound healing by promoting angiogenesis via FGFR1/ERK signaling. Biomed Pharmacother. 2020 Dec;132:110933. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5103 mL	12.5515 mL	25.1029 mL	62.7573 mL
	5 mM	0.5021 mL	2.5103 mL	5.0206 mL	12.5515 mL
	10 mM	0.2510 mL	1.2551 mL	2.5103 mL	6.2757 mL
	15 mM	0.1674 mL	0.8368 mL	1.6735 mL	4.1838 mL
	20 mM	0.1255 mL	0.6276 mL	1.2551 mL	3.1379 mL
	25 mM	0.1004 mL	0.5021 mL	1.0041 mL	2.5103 mL
	30 mM	0.0837 mL	0.4184 mL	0.8368 mL	2.0919 mL
	40 mM	0.0628 mL	0.3138 mL	0.6276 mL	1.5689 mL
	50 mM	0.0502 mL	0.2510 mL	0.5021 mL	1.2551 mL
	60 mM	0.0418 mL	0.2092 mL	0.4184 mL	1.0460 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Kanglexin

Epigenetics Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Alle NOD-like Receptor (NLR) Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle AMPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Kanglexin Related Classifications

Art. -Nr.: HY-164853